The NeurologyLive dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
June 27, 2022
Article
Net improvement of 1 grade or more on Extended Glasgow Outcome Scale was observed in 30.4% of the surgical group compared with 14.5% of those on standard medical care.
June 27, 2022
Article
Here's what is coming soon to NeurologyLive®.
June 26, 2022
Article
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.
June 25, 2022
Video
Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]
June 24, 2022
Article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 24, 2022.
June 23, 2022
Article
After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.
June 23, 2022
Article
The trial was terminated because of the expectation of enrollment not being feasible, driven by the recent CMS national coverage determination. The phase 4 confirmatory ENVISION trial is still ongoing.
June 22, 2022
Article
Over an 18-month treatment period, patients with prodromal to mild Alzheimer disease demonstrated similar increases in Clinical Dementia Rating-Sum of Boxes scores regardless of treatment with placebo or semorinemab.
June 22, 2022
Article
The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the major talking points regarding sleep quality, sleep disorders, and late-life neurocognitive issues.
June 20, 2022
Article
In the first NIH-backed study to evaluate an experimental prevention therapy in cognitively unimpaired persons at risk for Alzheimer disease, crenezumab showed small numerical, but not statistically significant differences compared with placebo.
CMSC 2022: Top Interviews and Key Takeaways
Zolgensma Further Demonstrates Impact in Treating Presymptomatic SMA, Regardless of 2 or 3 SMN2 Copies
Involving Patients in the Conversation About Parkinson Disease Treatment Approaches: Jill Farmer, DO, MPH
Decompressive Craniectomy Shows Greater Improvements in Traumatic Intracranial Hypertension Than Standard Treatment